|
C16ORF48 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.49349996206405E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.83419999480961E-08 |
| Normal-vs-Stage2 |
1.920180E-02 |
| Normal-vs-Stage3 |
4.83499995596048E-09 |
| Normal-vs-Stage4 |
9.645300E-04 |
| Stage1-vs-Stage2 |
3.727200E-01 |
| Stage1-vs-Stage3 |
5.755600E-02 |
| Stage1-vs-Stage4 |
4.758800E-01 |
| Stage2-vs-Stage3 |
5.679600E-02 |
| Stage2-vs-Stage4 |
2.678200E-01 |
| Stage3-vs-Stage4 |
7.423800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.91619958683975E-10 |
| Normal-vs-AfricanAmerican |
8.138100E-02 |
| Normal-vs-Asian |
8.564300E-02 |
| Caucasian-vs-AfricanAmerican |
5.473000E-01 |
| Caucasian-vs-Asian |
2.524200E-02 |
| AfricanAmerican-vs-Asian |
5.433800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.759800E-03 |
| Normal-vs-Female |
7.68890506819275E-11 |
| Male-vs-Female |
1.734340E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.08859999994981E-06 |
| Normal-vs-Age(41-60Yrs) |
2.65399999754834E-08 |
| Normal-vs-Age(61-80Yrs) |
1.65019999999183E-05 |
| Normal-vs-Age(81-100Yrs) |
2.956200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.094400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.968400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.877950E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.234000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.193400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.153200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.30569999993114E-07 |
| Classical-VS-Follicular |
2.521800E-03 |
| Classical-VS-Other |
5.599900E-02 |
| Classical-VS-Normal |
7.49549977641095E-10 |
| Tall-VS-Follicular |
1.26169996672587E-09 |
| Tall-VS-Other |
1.301560E-02 |
| Tall-VS-Normal |
1.62525548574877E-12 |
| Follicular-VS-Other |
6.342800E-01 |
| Follicular-VS-Normal |
1.473820E-01 |
| Other-VS-Normal |
9.832800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.98273999999499E-05 |
| Normal-vs-N1 |
1.844220E-02 |
| N0-vs-N1 |
9.716000E-01 |
|
|
